-

Pfizer Declares First-Quarter 2026 Dividend

Board of Directors approves quarterly cash dividend of $0.43 per share

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 first-quarter 2026 dividend on the company’s common stock, payable March 6, 2026, to holders of the Common Stock of record at the close of business on January 23, 2026. The first-quarter 2026 cash dividend will be the 349th consecutive quarterly dividend paid by Pfizer.

About Pfizer: Breakthroughs That Change Patients’ Lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For 175 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on X at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

Category: Financial

Contacts

Media Contact: PfizerMediaRelations@Pfizer.com

Investor Contact: IR@Pfizer.com

Pfizer Inc.

NYSE:PFE

Release Versions

Contacts

Media Contact: PfizerMediaRelations@Pfizer.com

Investor Contact: IR@Pfizer.com

More News From Pfizer Inc.

FDA Grants Priority Review for HYMPAVZI® (marstacimab) sBLA for the Treatment of Two Hemophilia A or B Patient Populations with Significant Medical Need

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the company’s supplemental Biologics License Application (sBLA) for HYMPAVZI® (marstacimab) to expand the approved indication to include the treatment of hemophilia A or B patients 6 years and older with inhibitors, and pediatric patients (ages 6 to 11) with hemophilia A or B without inhibitors. In the U.S., HYMPAVZI is currently approv...

Pfizer Launches Cost Savings Program on TrumpRx Lowering Drug Costs for Millions of Americans

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the launch of its program on TrumpRx, making innovative medicines more affordable and accessible to millions of Americans. Starting today, the program provides Americans a wide range of more than 30 medicines at a significant discount off list prices. This effort is part of Pfizer’s broader landmark Most Favored Nation (MFN) agreement with the U.S. government enabling patients to pay lower prices for their prescription medicines...
Back to Newsroom